Dr. Avinash Desai, Actinium's Chief Medical Officer, said, "The Actimab-A solid tumor program is highly novel and has the potential to address the high unmet need of patients receiving PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback